Francesco Marchesi1*, Luigi Toma2, Enea Gino Di Domenico3, Ilaria Cavallo3, Antonio Spadea1, Grazia Prignano3, Fulvia Pimpinelli3, Elena Papa1, Irene Terrenato4, Fabrizio Ensoli3 and Andrea Mengarelli1.
1 Hematology and Stem Cell Transplant Unit, I.R.C.C.S. Regina Elena National Cancer Institute (Rome, Italy).
2 Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, I.R.C.C.S. Regina Elena National Cancer Institute (Rome, Italy).
3 Microbiology and Virology, I.R.C.C.S. San Gallicano Dermatological Institute (Rome, Italy).
4 Biostatistics and Bioinformatic Unit, Scientific Direction, I.R.C.C.S. Regina Elena National Cancer Institute (Rome Italy).
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To the editor,
|Figure 1. Algorithm for febrile neutropenia treatment in enrolled patients.|
|Table 1. Clinical parameters and outcome comparison among the three patient cohorts.|